UCB strong outperformer among the Belgian stocks

Because of the huge profits of 49 percent this year the share belongs to one of the best shares of Belgium. Since the start of this year, the average Belgian stock rose year around 11 percent in value. Over the past 3 months the stock price increased (+26 percent). Since the start of this year, the average Belgian stock has gained year around 11 percent in value.

Returns UCB versus Belgian stocks

Buy & hold Returns stock UCB several periods, excluding dividend returns

Investors who invested in 2007 in the company's share now have a strong profit of 310 percent. Since 2012 the stock has a price gain of 61 percent. over the past 90 days the stock made a profit of 26 percent.

For this year UCB's revenue will be around 5,22 billion euros. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 4,91 billion euros.

Historical revenues and results UCB plus estimates 2020

fundamental data

The analysts expect for 2020 a net profit of 913 million euros. Most of the analysts anticipate on a profit per share of 4,86 euros. So the price/earnings-ratio equals 21,7.

Per share the analysts anticipate on a dividend of 1,23 euros per share. The dividend yield is then 1,17 percent. The average dividend yield of the pharmaceutical companies is a low 0,2 percent.

Newest target prices around 122 euros

The most recent recommendations for the pharmaceutical company are from Bryan Garnier, UBS and KBC Securities.

Based on the current number of shares UCB's market capitalization equals 19,92 billion euros. The UCB stock was the past 12 months quite unstable. Since last July the stock is even 44 percent higher. This year the stock price moved between 60 and 109 euro.

Historical stock prices UCB period 2007-2020

fundamental data ucb

Click here for dividend UCB. At 10.35 the stock trades 0,52 percent lower at 105,45 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.